AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.

Metadata

Provider:

Business Wire, Inc.

Retrieved on:

星期二, 四月 9, 2024

Information

Geotags:

EUROPE, UNITED STATES, NORTH AMERICA, FRANCE, CALIFORNIA

Organisation:

BRENUS PHARMA

摘要

Key Points:

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.
Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.
STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors.
Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured.

Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10).

“Efficacy of the STC-1010¹ a new allogeneic cancer vaccine in different colorectal cancer models” | Abstract 5003 https://doi.org/10.1158/1538-7445.AM2024-5003

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.

Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.

STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors. Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured. Metastasis reduction has also been shown with in-ovo model.

Results show the potential of STC-1010 in clinical settings to treat patients with colorectal cancer causing 9.7 million death per year.

George ALZEEB², [email protected], Innovation Manager Manager (Ph.D)
Céline GONGORA³, [email protected], Research Director, Head of Team Inserm U1194 “Drug resistances and new cancer treatment” (Ph.D)
Corentin RICHARD⁴, [email protected], Postdoctoral Bioiformatician (Ph.D)
Romain BOIDOT³, [email protected], Molecular Biologist (Ph.D)
Tanguy FORTIN⁵, [email protected], Chief Executive Officer (Ph.D)
Yan WANG⁶, [email protected], Scientist/R&D Project Manager (Ph.D)
Alban BESSEDE⁷, [email protected], Chief Executive Officer (Ph.D)
Benoit PINTEUR¹, [email protected], Chief Scientific Officer (Pharm D)
Lionel CHALUS¹, [email protected], Head of Technical Operation
Corinne TORTORELLI¹, [email protected], Senior Medical Lead (Pharm.D., Ph.D)
Paul BRAVETTI¹, [email protected], Chief Executive Officer (Pharm D, MSc)
François GHIRINGHELLI⁸, [email protected], Head of Team Inserm 1231 TIRECs «Therapies and Immune REsponse in CancerS », Director of early clinical unit CLIPP2, Professor of Oncology (M.D, PhD)

https://www.brenus-pharma.com/ | Follow us on LinkedIn

¹ STC-1010 is a next-generation cancer immunotherapy produced by Allogeneic STC's proprietary Brenus platform. It’s specifically designed to combat colorectal cancer including MSS and MSI-H populations in its first line of treatment for the first indication. STC Platform mimics relapse conditions and allows eduction of patient’s immune system against resistant tumor.

² Brenus Pharma, Lyon, France,

³ INSERM U1194 IRCM, Montpellier, France,

⁴ CNRS 6302, Dijon, France,

⁵ Anaquant, Lyon, France

⁶ Inovotion, La Tronche, France,

⁷ Explicyte, Bordeaux, France

⁸ Inserm 1231 CGFL, Dijon, France

View source version on businesswire.com: https://www.businesswire.com/news/home/20240409632375/en/